ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-Way Pagers

This study is currently recruiting participants.
Information provided by National Institute of Mental Health (NIMH)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-Way Pagers
Official Title  2-Way Pagers to Improve Schizophrenia Medication Adherence
Brief Summary

This study will determine whether using a pager improves medication adherence in people with schizophrenia.

Detailed Description

Schizophrenia is a life-long brain disorder affecting approximately 1 percent of Americans each year. Schizophrenia can be extremely disabling, causing people to hear voices, experience paranoia or hallucinations, and believe that others are controlling their thoughts. Many people with schizophrenia have difficulty with remembering their scheduled doctor's appointments and with taking their medication on time because of their mental illness. Many approved medications for schizophrenia must be taken several times a day and side effects such as drowsiness, dizziness, and even weight gain can deter a person from consistently taking their medication on time. Therefore, this study will determine whether a 2-way pager will help people with schizophrenia to remember their doctor's appointments and to take their medication on time.

Participants in this open-label study will first complete several written tests to assess skills such as memory, attention, and problem solving. Participants will also be asked questions regarding their current symptoms and medication regimen. Participants will then be randomly assigned to receive either treatment as usual or treatment as usual and a 2-way pager for 6 months. Participants who receive a 2-way pager will attend approximately four information sessions. During these sessions, participants will learn how to program the pager and use a specially designed medication bottle cap that will record the number of bottle openings and the date and time of each opening. At designated times, the pager will vibrate or beep, alerting participants to take their medication or attend a scheduled appointment. All participants will meet weekly with a staff member for the first month and then once a month for the remaining 5 months to complete several brief questionnaires on pager use, assess medication adherence, and discuss any symptoms experienced within the past week or month. Participants will be required to bring their medication to each meeting to ensure compliance.

Study Phase
Study Type  Interventional
Study Design  Supportive Care, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Primary Outcome Measure  Percent of prescribed doses taken as assessed by the Medication Event Monitoring System (MEMS) [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
Secondary Outcome Measure  Multidimensional Scale of Independent Functioning [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
Drug Attitude Inventory [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
Positive and Negative Symptom Scale (PANSS) [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
Self Appraisal of Illness Questionnaire [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
Quality of Life Interview (Short Version) [ Time Frame: Measured at Month 6 ] [ Designated as safety issue: No ]
Condition  Schizophrenia
Intervention  Device: 2-way pager
Behavioral: Treatment as usual
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Recruiting
Enrollment  80
Start Date  April 2006
Completion Date March 2009
Eligibility Criteria 

Inclusion Criteria:

  • Meets DSM-IV criteria for schizophrenia or schizoaffective disorder
  • Admitted to the Zucker Hillside Hospital for exacerbation of illness
  • Interest in improving medication adherence
  • Speaks English

Exclusion Criteria:

  • Presence of severe visual or motor impairments
  • Mental retardation
  • Neurologic disorder that may impact functioning such as seizures or vascular, neoplastic, traumatic, or infectious disorders affecting the brain
  • Prescribed a psychotropic drug in depot form
  • After hospital discharge, a living or treatment situation that includes dispensing of full medication regimen
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Contact: Cristina Gomes, BA     718-470-8975     cgomes@lij.edu    
Contact: Priya Matneja, BA     718-470-8953     pmatneja@lij.edu    
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00392236
Organization ID R34 MH074844
Secondary IDs †† DAHBR 96-BHA
Study Sponsor  National Institute of Mental Health (NIMH)
Collaborators ††
Investigators 
Principal Investigator:     Delbert G. Robinson, MD     North Shore Long Island Jewish Health System    
Information Provided By National Institute of Mental Health (NIMH)
Verification Date February 2008
First Received Date  October 23, 2006
Last Updated Date February 26, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers